Press Releases Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 01:45:00 04/05/2024 am IST			5-day change	1st Jan Change
17.14 ^USD	+1.96%		+11.08%	-20.13%

01/05	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial	CI
09/04	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial	01/05	GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04	AQ
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02	AQ
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02	GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02	AQ
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02	GL
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02	AQ
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	08/01	GL
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	08/01	AQ
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights	08/11	GL
MOMENTUM IN ALZHEIMER'S RESEARCH GUIDED BY THE BIOLOGY OF AGING TO BE HIGHLIGHTED IN SESSION MODERATED BY ALZHEIMER'S DRUG DISCOVERY FOUNDATION AT 2023 CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE	18/23/18	AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/23/09	AQ
ProFound Therapeutics Expands Leadership Team with Appointment of Klaus Urbahns as Chief Scientific Officer	26/23/26	AQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023	30/23/30	GL
ALLTRNA EXPANDS LEADERSHIP TEAM WITH APPOINTMENTS OF CHIEF SCIENTIFIC OFFICER AND CHIEF TECHNOLOGY OFFICER	16/23/16	AQ
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines	15/23/15	AQ
ALLTRNA ANNOUNCES SERIES B RAISE OF $109 MILLION TO ADVANCE TRNA MEDICINES FOR STOP CODON DISEASE	10/23/10	AQ
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights	09/23/09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Press Releases

Filters